BioRem Inc. (CVE:BRM – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Thursday. The stock traded as high as C$4.46 and last traded at C$4.27, with a volume of 25,080 shares. The stock had previously closed at C$4.44.
BioRem Price Performance
The company has a debt-to-equity ratio of 14.17, a current ratio of 2.04 and a quick ratio of 1.08. The stock has a market cap of C$68.07 million, a price-to-earnings ratio of 12.50 and a beta of 0.78. The stock has a fifty day moving average of C$3.62 and a 200 day moving average of C$3.14.
Insider Activity at BioRem
In other news, Director Derek Webb sold 28,700 shares of the company’s stock in a transaction on Monday, August 24th. The shares were sold at an average price of C$3.82, for a total value of C$109,634.00. Following the sale, the director directly owned 362,370 shares of the company’s stock, valued at C$1,384,253.40. This represents a 7.34% decrease in their position. 1.90% of the stock is owned by company insiders.
BioRem Company Profile
BioRem Inc, a clean technology engineering company, designs, manufactures, distributes, and sells air pollution control systems that are used to eliminate odors, volatile organic compounds (VOCs), and hazardous air pollutants (HAPs). It offers biofilters for the removal of odors, H2S, VOCs, and HAPs; and biotrickling filters for applications of high levels of H2S or other water-soluble VOCs. The company also provides multi-stage systems to remove odors from various municipal/urban wastewater treatment processes; biogas desulfurization systems; dry scrubber adsorption systems; and cannabis odor control systems.
Featured Articles
- Five stocks we like better than BioRem
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for BioRem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioRem and related companies with MarketBeat.com's FREE daily email newsletter.
